Abbott Laboratories (ABT)

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

Jim Cramer discusses bonds and also talks about why panicking off the Fed is a superbad idea.

Tech rotation, oil and Fed rate hike keep markets on even (make that flat) keel. Several portfolio positions get beefed up.

A rotation that started as the minor chord of the rotational symphony and is now the major one.

Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.

In turn, this will increase the company's profit margins.

As investors book profits in tech names, we want to let the sellers tire themselves out before making a big move.

Barring a close below $46, we are likely to see ABT remain firm and work higher.

We exited HP Enterprise and brought Abbott Labs in from the Bullpen.

We really want to shake out the weak hands here.

After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.

We pretty much saw this coming.

Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Bristol-Myers will conduct the study and both companies will evaluate the findings.

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

We are exiting HPE to build cash and make room for another potential name.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CIO, FLO, TGP Downgrades: ABT, ADSK, AEG, DISCA, GPS, GSM, KEYS, NVFY Initiations: BATRA, BATRK Read on to get TheStreet Quant Ratings' detailed report:

Analysts also gave the company a $45 price target

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.

New Cardiac Ablation Catheter Integrates with 3D Mapping System to Advance the Treatment of Atrial Fibrillation

From Abbott Labs to Wynn, these names rate checking out.

THE NEW CONFIRM RX™ ICM AUTOMATICALLY CAPTURES VITAL CARDIAC INFORMATION AND RELAYS DATA TO PHYSICIANS VIA THE MYMERLIN™ MOBILE APP ENABLING REMOTE MONITORING OF IRREGULAR HEART RHYTHMS

It's a wonder to me how split this market really is.

- FREESTYLE® LIBRE SYSTEM ELIMINATES ROUTINE FINGER STICKS(1) FOR GLUCOSE MEASUREMENTS AND REQUIRES NO FINGER STICKS FOR CALIBRATION